Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987858 | 0.79 | CA1 (0.44) | PTGS2CYP2C9TP53SLC6A3CA1 | |
| SCHEMBL28173737 | 0.78 | AKR1C3 (0.43) | PTGS2PTGS1AKR1C3AKR1C2ALB | |
| SCHEMBL59197 | 0.78 | PTGS2 (0.74) | PTGS2PTGS1AKR1C3CYP2C9AKR1C2 | |
| SCHEMBL464581 | 0.77 | PTGS2 (0.57) | PTGS2PTGS1AKR1C3CYP2C9AKR1C2 | |
| SCHEMBL19962169 | 0.77 | NOS3 (0.50) | PTGS2TP53SLC6A3CA1CA2 | |
| SCHEMBL13455319 | 0.77 | CA1 (0.44) | PTGS2CYP2C9TP53SLC6A3CA1 | |
| Alanine SCHEMBL28291828 | 0.75 | PTGS2 (0.43) | PTGS2PTGS1ALBTP53CA1 | |
| SCHEMBL25403273 | 0.75 | NR1I2 (0.53) | PTGS2PTGS1CYP2C9LMNAALB | |
| SCHEMBL17823121 | 0.75 | TP53 (0.41) | PTGS2ALBTP53SLC6A3CA1 | |
| SCHEMBL14032361 | 0.75 | TBXAS1 (0.44) | PTGS2PTGS1AKR1C3CYP2C9AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214912-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | VAXCYTE, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12252454-B2 | Carrier-protein polysaccharide conjugation methods | VAXCYTE, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240200070-A1 | EXPANDING THE CHEMICAL SUBSTRATES FOR GENETIC CODE REPROGRAMMING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2024-06-20 | — | — | US | disclosed |
| EP-4200268-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | VAXCYTE, INC. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230183147-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | VAXCYTE, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20220125907-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022040266-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | VAXCYTE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3946443-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-114025789-A | Optimized cell-free synthesis of invasive plasmid antigen B and related compositions and methods of use | VAXCYTE公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2020205584-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214912-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | DDOST, STT3B, STT3A | PTGS2 4122/4885PTGS1 4545/4885AKR1C3 3321/4885 |
| US-20230183147-A1 | CARRIER-PROTEIN POLYSACCHARIDE CONJUGATION METHODS | DDOST, STT3B, STT3A | PTGS2 4122/4885PTGS1 4545/4885AKR1C3 3321/4885 |
| US-12252454-B2 | Carrier-protein polysaccharide conjugation methods | DDOST, STT3B, STT3A | PTGS2 4122/4885PTGS1 4545/4885AKR1C3 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.